Figure - available via license: Creative Commons Attribution 4.0 International
Content may be subject to copyright.
Clinical characteristics of alopecia areata (AA) and rheumatoid arthritis (RA) patients on tofacitinib.
Source publication
Tofacitinib is a Janus kinase inhibitor (JAKi) that is used off-label for the treatment of alopecia areata (AA). Its boxed warning includes an increased risk of serious adverse events (SAEs) based on the results of a safety trial in rheumatoid arthritis (RA) patients taking the medication. The purpose of this study was to investigate the difference...
Contexts in source publication
Context 1
... racial proportions of White, Black or African American, Asian, and other/unknown race patients in the RA cohort were 71%, 10%, 3%, and 14%, respectively. In the AA cohort, the racial proportions of White, Black or African American, Asian, and other/unknown race patients were 68%,14%, 4%, and 18%, respectively (Table 1). ...Context 2
... the RA cohort, 39% had hypertension, 20% were affected by obesity, 14% had type 2 diabetes mellitus, and 10% experienced nicotine dependence. In the AA cohort, the prevalences differed with 21% (p-value < 0.0001) affected by hypertension, 11% (p-value < 0.0001) by obesity, 10% (p-value < 0.0001) by type 2 diabetes mellitus, and 4% (p-value < 0.0001) by nicotine dependence (Table 1). ...Context 3
... percentages of medication use in the RA cohort were as follows: 53% used methotrexate, 64% used prednisone, 5% used rituximab, 34% used hydroxychloroquine, 5% used cyclosporine, 5% used azathioprine, and 2% used mycophenolate mofetil. In the AA cohort, the percentages of medication use were as follows: 21% used methotrexate (p-value < 0.0001), 37% used prednisone (p-value < 0.0001), 1% used rituximab (p-value < 0.0001), 8% used hydroxychloroquine (p-value < 0.0001), 5% used cyclosporine (p-value = 0.56), 4% used azathioprine (p-value = 0.14), and 4% used mycophenolate mofetil (p-value < 0.0001) ( Table 1). ...Context 4
... concomitant immunosuppressive medication use rate was also higher in the RA cohort compared to that of the AA cohort, with exception to cyclosporine and azathioprine. It is important to note that the increased utilization of other immunosuppressive medications and biologic agents by rheumatoid arthritis (RA) patients may have influenced their overall health outcomes (Table 1). ...